Preferences help
enabled [disable] Abstract
Number of results
2011 | 65 | 3 | 77–81
Article title

Cefoselina – nowa cefalosporyna czwartej generacji

Title variants
Cefoselis – a novel 4th generation cephalosporin
Languages of publication
Siarczan cefoseliny jest nową cefalosporyną do podawania parenteralnego, wprowadzoną do lecznictwa w Japonii 9 sierpnia 1998 r. Cefoselina, jak inne betalaktamy, działa przeciwbakteryjnie przez łączenie się z białkami wiążącymi penicylinę. Wykazuje spektrum działania wobec bakterii tlenowych i beztlenowych Gram-dodatnich oraz Gram-ujemnych. Wskazana jest w leczeniu infekcji wywołanych przez Staphylococcus i Pseudomonas, a zwłaszcza w zakażeniach dróg oddechowych i moczowych. Zalecane dawkowanie cefoseliny to 1 g dwa razy dziennie w postaci wlewu dożylnego. Czas trwania terapii 5–14 dni.
Cefoselis sulphate is a new parenteral cephalosporin, which was launched into therapy in Japan on 9 September, 1998. Cefoselis, like all the other beta-lactams, exhibits its bactericidal eff ects by binding to penicillinbinding proteins. It has a spectrum of activity that covers aerobic and anaerobic gram-positive and gram-negative bacteria. Cefoselis has been approved to treat infections caused by Staphylococcus and Pseudomonas especially respiratory and urinary tract infections. The recommended dose of cefoselis is 1 g twice a day as an intravenous infusion. The duration of therapy is from 5 to 14 days.
Physical description
  • Katedra i Zakład Chemii Farmaceutycznej Wydziału Farmaceutycznego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu ul. Grunwaldzka 6 60-780 Poznań tel. 61 854 66 49
  • Katedra i Zakład Chemii Farmaceutycznej Wydziału Farmaceutycznego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
  • 1. Meszaros J. Cefalosporyny – 50 lat po odkryciu. Przew. Lek. 2000; 1: 93–98.
  • 2. Marshall F., Blair J. The cephalosporins. Mayo Clin. proc. 1997; 74 187–195.
  • 3. Donadio S., Maffi oli S., Monciardini P., Sosio M., Jabes D. Antibiotic discovery in the twenty-fi rst century: current trends and future perspectives. J. Antibiot. 2010; 63: 423–430.
  • 4. Astellas press release dated September 16, 2005. Available at corporate/news/fujisawa/980907.html
  • 5. Zając M., Pawełczyk E., Jelińska A. Chemia leków. Wydawnictwo Naukowe Akademii Medycznej im. Karola Marcinkowskiego, Poznań 2006.
  • 6. King A., Bethune L., Phillips I. The Comparative In Vitro Activity of FK-037 [Cefoselis], a New Broad-Spectrum Cephalosporin. Clin. Microbiol. Infect. 1995; 1: 13–17.
  • 7. Ohki H. i wsp. Studies on 3’-quaternary ammonium cephalosporins-IV. Synthesis and antibacterial activity of 3’-[2-alkyl-3- -aminopyrazolinum]cephalosporins related to FK037. Bioorg. Med. Chem. 1997; 5: 1685–1694.
  • 8. Watanabe N. Newer antipseudomonal cephalosporins. J. Chemother. 1996; 8: 48–56.
  • 9. Higashi Y., Wakabayashia A., Matsumotoa Y., Watanabea Y., Ohno A. Role of Inhibition of Penicillin Binding Proteins and Cell Wall Cross-Linking by Beta-Lactam Antibiotics in Low- and High-Level Methicillin Resistance of Staphylococcus aureus. Chemotherapy 1999; 45: 37–47.
  • 10. Giamarellos-Bourboulis E.J. i wsp. Invitro activity of FK 037 [Cefoselis], a novel 4th generation Cephalosporin, compared to Cefepime and Cefpirome on nosocomial Staphylococci and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 2000; 36: 185–191.
  • 11. Casey J., Pichichero M. Meta-analysis of cephalosporin versus penicillin treatment of group A Streptococcal tonsillopharyngitis in children. Pediatrics 2004; 113: 866–882.
  • 12. Fu K.P., Foleno B.D., Lafredo S.C., Lococo J.M., Isaacson D.M. In Vitro and In Vivo Antibacterial Activities of FK037, a Novel Parenteral Broad-Spectrum Cephalosporin. Antimicrob. Agents. Chemother. 1993; 37: 301–307.
  • 13. Kato N., Kato H., Tanaka Y., Bando K., Watanabe K., Ueno K. In Vitro Activity of FK037, a New Parenteral Cephalosporin, against Anaerobic Bacteria. Antimicrob. Agents. Chemother. 1993; 37: 957–961.
  • 14. Neu H.C., Chin N., Huang H. In Vitro Activity and 3-Lactamase Stability of FK-037, a Parenteral Cephalosporin. Antimicrob. Agents. Chemother. 1993; 37: 566–573.
  • 15. Akio U.,Yoshitomo M., Kenshi S. Effi cacy of cefoselis against various infections in hematological diseases. Antibiot. Chemother. 2003; 19: 1806–1815.
  • 16. Yoshimi M. i wsp. Effi cacy of cefoselis against mixed infection caused by penicillin- resistant Strpetococcus pneumoniae [PRSP] and BETA-1actamase-negative ampicillin-resistant Haemophilus infl uenzae [BLNAR]. Jpn. J. Chemother. 2000; 48: 516–523.
  • 17. Masuda N., Gotoh N., Ohya S., Nishino T. Quantitative Correlation between Susceptibility and OprJ Production in NfxB Mutants of Pseudomonas aeruginosa. Antimicrob. Agents. Chemother. 1996; 40: 909–913.
  • 18. Climoa M.W., Markowitz S.M., Williams D.S., Hale-Cooper C.G., Archer G.L. Comparison of the in-vitro and in-vivo effi cacy of FK037, vancomycin, imipenem and nafcillin against Staphylococcal species. J. Antimicrob. Chemother. 1997; 40: 59–66.
  • 19. Hanaki H., Hiramatsu K. Combination eff ect of teicoplanin and various antibiotics against hetero-VRSA and VRSA Kansenshogaku Zasshi 1999; 73: 1048 –1053.
  • 20. Kuriyama T., Karasawa T., Nakagawa K., Nakamura S., Yamamoto E. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 􀈕-lactam antibiotics Oral Microbiol. Immunol. 2002; 17: 285–289.
  • 21. Wise R., Andrews J.M., O’neill P., Jolley A., Fowler C., Rogge M.C. Pharmacokinetics and Distribution in Tissue of FK-037, a New Parenteral Cephalosporin. Antimicrob. Agents Chemother. 1994; 38: 2369–2372.
  • 22. Wise R Tissue penetration of the fourth generation parenteral cephalosporins. J. Chemother. 1996; 8: 63–70.
  • 23. Ueo H., Motohashi H., Katsura T., Inui K. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem. Pharmacol. 2005; 70: 1104–1113.
  • 24. Malliga E. i wsp. 􀈕-Lactam Antibiotics as Substrates for OCTN2, an Organic Cation/ Carnitine Transporter. J. Biol. Chem. 2000; 275: 1699–1707.
  • 25. Nagata M. Yasuhara M. Eff ect of Experimental Renal Failure on the Pharmacodynamics of Cefoselis-Induced Seizures in Rats. Biol. Pharm. Bull. 2001; 24: 1049 –1052.
  • 26. Ohtaki K. i wsp. Cefoselis, a 􀈕-lactam antibiotic, easily penetrates the blood- -brain barrier and causes seizure independently by glutamate release. J. Neural. Transm. 2004; 111: 1523–1535.
  • 27. Chimura T. i wsp. Clinical eff ects of cefoselis [CFSL] on infections in obstetric and gynecologic fi eld and prevention of postoperative infections. Jpn. J. Antibiot. 2000; 53: 637–641.
  • 28. Kaname O., Satoru M., Jiro W., Sadao H. Consideration of risk factors for the development of central nervous system symptoms upon administration of cefoselis. Jpn. J. Chemother. 2000; 48: 285–294.
  • 29. Yoshisada S. i wsp. Adverse eff ects of cefoselis on the central nervous system: Identifi cation of risk factors and estimation of incidence. Jpn. J. Chemother. 2002; 50; 730–747.
  • 30. Sugimoto M. i wsp. The 􀈕-lactam antibiotics, penicillin-G and cefoselis have diff erent mechanisms and sites of action at GABAA receptors. Br. J. Pharmacol. 2002; 135: 427–432.
  • 31. Yamazaki S. i wsp. Intracerebroventricular injection of the antibiotic cefoselis produces convulsion in mice via inhibition of GABA receptors. Pharmacol. Biochem. Behav. 2002; 74: 53–59.
  • 32. Sugimoto M. i wsp. Evidence for the involvement of GABAA receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003; 45: 304–314.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.